LegisTrack
Back to all bills
HR 5415119th CongressIn Committee

Nitazene Control Act of 2025

Introduced: Sep 16, 2025
Sponsor: Rep. Vindman, Eugene Simon [D-VA-7] (D-Virginia)
Civil Rights & JusticeHealthcare
Standard Summary
Comprehensive overview in 1-2 paragraphs

The Nitazene Control Act of 2025 would permanently place the class of benzimidazole-opioids known as nitazenes (2-benzylbenzimidazole opioids) into Schedule I of the Controlled Substances Act. The bill adds a broad, class-wide definition to Schedule I that covers nitazenes, their isomers, esters, ethers, salts, and related compounds, including numerous structural variants. It also requires these substances to exhibit mu-opioid receptor agonist activity. The measure explicitly treats substances that were previously scheduled on a temporary basis as permanently scheduled as of enactment and notes that research using these substances must still follow proper registration and scheduling compliance. Additionally, the bill acknowledges that pathways created by the HALT Fentanyl Act for research involving Schedule I substances would apply to nitazenes as well. In short, the bill aims to close gaps in enforcement by making nitazenes and likely new analogs permanently illegal under Schedule I, while clarifying research pathways and ongoing regulatory requirements.

Key Points

  • 1Permanently schedules nitazenes as Schedule I under the Controlled Substances Act, making their possession, manufacture, and distribution subject to strict control without medical acceptance.
  • 2Establishes a broad Schedule I class for 2-Benzylbenzimidazole opioids, including their isomers, esters, ethers, salts, and a wide range of structural variants, provided they are mu-opioid receptor agonists.
  • 3Includes specific named nitazenes (e.g., etonitazene, clonitazene, metonitazene, isotonitazene, protonitazene, and several others) within the permanent scheduling framework.
  • 4Removes temporary scheduling status for substances that were temporarily scheduled under prior provisions, deeming them permanently scheduled as of enactment.
  • 5States that the bill does not authorize new research without proper registration and scheduling compliance, preserving regulatory safeguards; notes that research pathways under the HALT Fentanyl Act apply to scheduled nitazenes as well.

Impact Areas

Primary group/area affected:- Public health and safety: reduced availability of nitazenes in the illicit market, potential decrease in overdose fatalities involving these drugs.- Law enforcement and regulatory agencies: clearer, class-wide prohibitions and enforcement authorities for nitazenes and their analogs.Secondary group/area affected:- Medical and scientific research institutions: ongoing need for proper registration and scheduling compliance to study these substances; potential hurdles for legitimate research due to Schedule I status.Additional impacts:- Public health planning and treatment programs may need to adjust to the tighter controls and the shift in drug availability.- Potential impact on penalties and criminal prosecutions for those involved in production, distribution, or possession of nitazenes.- International implications may arise from harmonization of scheduling and enforcement efforts with other countries observing similar controls.
Generated by gpt-5-nano on Oct 8, 2025